New York-based brain-computer interface company Precision Neuroscience Corporation has raised $41 million in Series B funding, bringing the company’s total funding to $53 million.
Fourrepont Capital Partners led the round with participation from Alumni Ventures, Draper Associates, Mubadala Capital and re.Mind Capital. Existing investors Steadview Capital and B Capital Group also contributed.
Precision will use this funding to expand its team and advance product development. The company plans to seek regulatory review from the FDA in the coming months.
Precision Neuroscience CEO Michael Mager said in a statement: “To get to this world, brain-computer interface technology needs to move from the lab to the clinic, and Precision is excited to take on that challenge.”
Atomic AI, a biotech company focused on technology-enabled drug discovery, has launched a $35 million Series A round led by Playground Global, bringing the company’s total funding to $42 million.
Factory HQ, 8VC, Greylock, AME Cloud Ventures, NotBoring, Angel Investors (Nat Friedman, Former CEO of GitHub, Neal Khosla Doug Mohr, CEO of Curai, UC Berkeley Professor and Co-Founder of Arc Institute) Patrick Hsu) also participated in the round.
The company aims to use machine learning to create RNA-targeting molecules and RNA-based medicines and tools. Models based on RNA structure datasets and large-scale in-house experimental wet lab biology.
Atomic AI founder and CEO Raphael Townshend said in a statement: “Atomic AI aims to be at the cutting edge of AI, RNA and structural biology. We are creating a whole new field of drug discovery.”
San Francisco-based Mighty Health, a lifestyle company that offers exercise, nutrition and daily wellness programs for people over 50, raised $7.6 million in funding jointly led by Will Ventures and GFT Ventures. bottom.
AARP also participated in the round along with Immad Akhund, CEO of startup banking company Mercury. Baselayer Ventures, the strategic arm of VF Corporation. Hyper, accelerator program. Z Venture Capital, the strategic venture arm of messaging app LINE. Existing investors also contributed to this round.
The funds will be used to launch multiple chronic disease programs and expand strategic partnerships.
Isaiah Kacyvenski, co-founder and managing partner of Will Ventures, said, “We love how the Mighty Health platform can address multiple needs of multiple chronic populations at once through radical lifestyle changes. It eliminates the need for seniors to use multiple apps and coaches.” statement.
Lithuania-based Oxipit, a provider of AI-enabled medical imaging tools, has raised $4.9 million in funding led by Taiwania Capital, Coinvest Capital and Practica Capital, with angel investors.
The company’s ChestLink application produces reports from X-ray studies of patients who show no abnormalities. Oxipit also offers a virtual radiologist assistant called Oxipit Quality. It compares radiology reports with diagnostic images to determine if there are any oversights in the reports.
The company will use the funding to further develop its AI-based applications and expand market access in new geographic regions with a focus on the UK market.
MedCrypt, a cybersecurity provider for medical device manufacturers, has extended its Series B funding round after receiving additional funding from Dexcom Ventures, bringing the company’s total funding to $36.4 million.
The extension will be made after the company has received A $25 million Series B funding was raised in November, bringing the company’s total funding to $34.4 million at that time.
Additional funding from the expansion will be used to grow MedCrypt’s engineering team.
